For sales

Highlights from the Week of 18th May – 25th May in the world of pharma and healthcare!

Highlights from the Week of 18th May 2026 - 25th May 2026 ( FDA, Approval ) AstraZeneca and Daiichi Sankyo gets FDA approval for its DATROWAY to treat adults with unresectable or metastatic TNBC ( FDA, Approval ) FDA approves AstraZeneca's BAXFENDY, an aldosterone synthase inhibitor, for the treatment of hypertension in combination with other antihypertensives ( FDA, Approval ) Bio-Thera and Accord BioPharma gets FDA approval for IMMGOLIS and IMMGOLIS INTRI, a biosimilar for the treatment of adults with moderately to severely active rheumatoid arthritis and ulcerative colitis ( CHMP, Positive Opinion ) Merck gets positive CHMP opinion for KEYTRUDA in combination with PADCEV as neoadjuvant treatment and as adjuvant treatment post radical cystectomy for adults with resectable MIBC Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.